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Summary Paradoxical embolism is a possible cause of ischemic stroke, particularly in younger
patients without any other cause, i.e. cryptogenic stroke, and a patent foramen ovale is
the most frequently assumed cause. The contrast transcranial Doppler monitoring mode has
a sensitivity that is comparable to contrast transesophageal echocardiography for detection
of a right-to-left shunt, however, the contrast transesophageal echocardiography remains the
‘‘golden standard’’ for the detection of a patent foramen ovale. Diagnostic studies that can
identify a patent foramen ovale may be considered for prognostic purposes. In most cases, how-agent;
Transesophageal
echocardiography;
ever, it is difﬁcult to establish a ﬁrm etiological association and the debate about medical or
interventional management is ongoing. Other possible causes of right-to-left shunting leading
to cerebral complications like pulmonary arteriovenous malformations have also been noted
but are rarely discussed.
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atients with cryptogenic stroke should be screened for
ossible paradoxical cerebral embolism via a cardiac or pul-
onary right-to-left shunt (RLS).
There is evidence for an increased prevalence of patent
oramen ovale (PFO) in cryptogenic stroke, in both younger
1—5] and elderly patients [6]. An atrial septal aneurysm
ASA) may increase the stroke risk as well, whether occurring
lone or combined with a PFO [2,5]. Diagnostic studies that
an identify PFO with RLS or ASA may be considered for prog-
ostic purposes [7]. Echocardiography is recommended in
elected stroke and TIA patients and is particularly required
n patients with suspected paradoxical embolism and no
Opether identiﬁable causes of stroke [8]. Transesophageal
chocardiography (TEE) is superior to transthoracic echocar-
iography for evaluation of the aortic arch, left atrium, and
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Open access under CC BY-NC-ND license.trial septum [9] and represents the ‘‘golden standard’’
o establish the presence of a RLS and a PFO. The con-
rast transcranial Doppler (cTCD) monitoring mode has a
ensitivity that is comparable to contrast TEE (cTEE) for
etection of a PFO with RLS. Its diagnostic sensitivity ranges
rom 70% to 100% and the speciﬁcity is more than 95%
10,11].
Although positive cTCD studies in pulmonary RLS have
een described, only cTEE allows localization of the RLS
o the cardiac or pulmonary level [12—15]. The distinc-
ion between cardiac and pulmonary shunts based on the
ime window of contrast appearance and contrast amount
hunted is unreliable by cTCD [13,16].
cTCD allows estimation of the shunt size by quantiﬁ-
ation and categorization of the contrast shunted. The
esults are comparable with shunt quantiﬁcation using
TEE [3,11,17—21]. Large RLS assessed by cTCD have been
eported to be associated with a higher risk of ﬁrst and recur-
ent stroke, particularly with cryptogenic stroke [17,22]. In
ss under CC BY-NC-ND license.ontrast, results of a study showed that massive RLS sized
ith TCD were not an independent risk factor for recur-
ent stroke [18]. Therefore, the clinical signiﬁcance of cTCD
hunt sizing remains unclear.
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Table 1 Summary of test procedures for detection of right-to-left shunt with ultrasound contrast agent and transcranial Doppler
sonography ([16], modiﬁed).
Preparation of the patient and TCD recording
Supine position. Insert 18-gauge needle — preferred over a 20-gauge needle to increase the sensitivity [56] — into (right)
cubital vein. A higher sensitivity is reported by using the femoral vein as injection site [43] which is, however, more
uncomfortable for the patient. Insonate (if possible both) middle cerebral arteries (MCA), bilateral recordings increase the
sensitivity compared with unilateral insonation [12,34]. In case of insufﬁcient acoustic bone window, transforaminal
insonation of the basilar artery might be an alternative approach [57].
Preparation of contrast agent and injection
Syringe I: 9ml saline; syringe II: 1ml air. Connect both syringes with three-way stopcock connected with a short ﬂexible line to
an intravenous line of 18-gauge with the patient. Exchange air/saline mixture vigorously between the syringes at least ten
times. Inject immediately as a bolus. In case of little or no detection of microembolic signals, repeat the examination with
Valsalva maneuver. Commercially traded contrast agents should be prepared according to the manufacturer’s instructions.
Application of Valsalva maneuver
The patient should start with Valsalva maneuver on examiner’s command 5 s after injection of the contrast agent; the control
of an adequate Valsalva maneuver will be performed by assessment of the reduction of peak ﬂow velocity of the TCD curve.
Overall Valsalva maneuver duration should be 10 s.
Evaluation of test results
Categorization (for unilateral testing, values for bilateral monitoring in parentheses): (1) 0 microembolic signals (negative
result); (2) 1—10 (1—20) microembolic signals; (3) >10 (>20) microembolic signals, but no curtain; (4) curtain or shower of
microembolic signals, where a single signal cannot be discriminated within the TCD spectra. The microembolic signal count
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The impact of cTCD in RLS detection has been studied in
a number of conditions other than cerebrovascular disease;
however, the grade of evidence from these studies is low to
moderate: a signiﬁcant association was reported between
the degree of cTCD sized shunting and the number of sig-
nal abnormalities on MRI in asymptomatic sport divers [23].
Divers with RLS show a higher risk of decompression sickness
[24]. There is evidence of an increased prevalence of PFO
in patients with migraine with aura [25], supported by cTCD
studies [26,27]. Furthermore, cTCD has been described to
be useful to detect residual shunting following transcatheter
closure of a PFO [28].
Depending on methodological factors, cTCD results vary
considerably. Therefore, criteria of the examination tech-
nique were established by an International Consensus
Meeting. The goal was a standardized approach and minimal
variability for RLS detection by cTCD [16]. The examina-
tion technique recommended by this Consensus Meeting is
summarized in Table 1.
Fig. 1 shows a video demonstration of a positive con-
trast study in a patient with large PFO. Additional data are
available also from publications summarizing the impact and
technique of cTCD for diagnosis of PFO [29,30].
cTCD uses air-containing echo contrast agents (CAs)
which normally are unable to pass the pulmonary capil-
lary bed. The diagnosis of a RLS by cTCD is established if
TCD observes microembolic signals after contrast injection.
However, the minimal amount of microembolic signals sug-
gestive of a clinically relevant RLS is not established [16].
Different authors require different numbers of microem-
bolic signals for the diagnosis of a PFO. They range from a
minimum of one microembolus to more than ﬁve microem-
boli. In addition, the time from contrast injection to signal
detection ranges from 6 to 10 cardiac cycles or from 4 s
to 24 s [31—33]. Most authors used agitated saline solution
as contrast agent [4,18,33—39] or D-galactose Mb solution
(
p
aition and Valsalva maneuver.
Echovist®) [12,32,34,40—46]. Only few authors used other
gents such as Oxypolygelatine (Gelifundol®, Gelofusin®)
3,31,39]. A sensitivity up to 100% was achieved by both
chovist® [42,47] and agitated saline solution [4,35,38]. The
onsensus Meeting recommended using the saline/air mix-
ure. Saline/air mixture is not subject to local approval
ules and has proven as effective as Echovist® in numerous
tudies. However, Echovist® is out of use in most countries
ecause this CA is not longer commercially available.
ecommendations
n younger stroke patients, studies that can identify PFO or
SAmay be considered for prognostic purposes (class II, level
). Echocardiography is recommended in selected stroke
nd TIA patients, and particularly in cryptogenic stroke and
hen paradoxical embolism is suspected (class III, level
). TCD is probably useful to detect cerebral microembolic
ignals in a wide variety of cardio- and cerebrovascular dis-
rders or procedures (classes II—IV, level B). Standardized
echnique cTCD has a sensitivity similar to cTEE for detec-
ion of a PFO with RLS (class II, level A) but does not provide
nformation of the anatomic location of the shunt or the
resence of an ASA. The examination should be performed
ccording to the instructions of the International Consensus
onference [16] (class II, level A). Although cTCD provides
nformation about the size of the shunt, the clinical useful-
ess remains to be determined (level C). cTEE remains the
‘golden standard’’ for the detection of PFO. However, cTCD
an be used as a minimally invasive screening test before
TEE or as an alternative method if cTEE is not available
classes III—IV, level C).
Uncertainties exist regarding optimal treatment of
aradoxical cerebral embolism and therapeutic consider-
tions have focussed primarily on the management of
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FO. Although international guidelines [48,49] recommend
ntiplatelet therapy as ﬁrst line strategy for treating stroke
atients with PFO, transcatheter closure has become com-
on practice in many centres and is one of the most frequent
nterventional procedures performed in adult congenital
eart disease [50]. Unfortunately, results from large ran-
omized trials [51—54] that compare interventional closure
f a PFO with medical therapy regarding the prevention of
urther cerebral ischemic events do not yet exist or have just
een reported at meetings [55]. Therefore individual coun-
elling is variable and the beneﬁt of either strategy largely
nknown.
ppendix A. Supplementary data
upplementary data associated with this arti-
le can be found, in the online version, at
ttp://dx.doi.org/10.1016/j.permed.2012.03.003.
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